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Abstract
A new enantiomeric synthesis utilizing classical resolution provided two novel series of optically
active inhibitors of cholinesterase: (−)- and (+)- O-carbamoyl phenols of tetrahydrofurobenzofuran
and methanobenzodioxepine. An additional two series of (−)- and (+)-O-carbamoyl phenols of
pyrroloindole and furoindole were obtained by known procedures, and their anticholinesterase
actions were similarly quantified against freshly prepared human acetyl- (AChE) and
butyrylcholinesterase (BChE). Both enantiomeric forms of each series demonstrated potent
cholinesterase inhibitory activity (with IC50 values as low as 10 nM for AChE and 3 nM for BChE),
with the exception of the (+)-O-carbamoyl phenols of pyrroloindole that lacked activity (IC50 values
> 1 µM). Based on the biological data of these four series, a SAR analysis was provided by molecular
volume calculations. In addition, a probable transition state model was established according to the
known X-ray structure of a transition state complex of Torpedo californica AChE-m-
(N,N,N,trimethylammonio)-2,2,2-trifluoroacetophenone (TcAChE-TMTFA). This model proved
valuable in explaining the enantio-selectivity and enzyme subtype selectivity of each series. These
carbamates are more or similarly potent to anticholinesterases in current clinical use; providing not
only inhibitors of potential clinical relevance but also pharmacological tools to define drug-enzyme
binding interactions within an enzyme crucial in the maintenance of cognition and numerous systemic
physiological functions in health, aging and disease.
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Dementia of the Alzheimer’s type afflicts some 4.5 million Americans and some 18 million
people worldwide. Based on the ‘cholinergic hypothesis’ of memory, the depletion of its
neurotransmitter, acetylcholine (ACh), and loss of associated synapses during the progression
of Alzheimer’s disease (AD),1,2 cholinesterase inhibitors (ChEIs) have been synthesized and
developed to clinical practice to ameliorate the associated cognitive symptoms.3 This is
achieved by reducing the rate of hydrolysis of ACh in brain and thereby augmenting its
cholinergic activity. Although ChEIs and the recently FDA approved drug, memantine, are the
only ones to have consistently induced improvements in cognitive function in mild to moderate
AD,4 such improvements are, unfortunately, generally modest. Indeed, recent clinical trials
have triggered debate as to the relevance of the benefit of this drug class.5,6 Such concern has
prompted two avenues of research. One to develop a new generation of ChEIs with activity
beyond the modest symptomatic one associated with initial agents, and another to optimize
current agents based on a greater understanding of enzyme/inhibitor interactions. Our research
focus has been to undertake both, simultaneously.
A classical ChEI, used to elucidate the original nature of chemical transmission of nerve action
and the cholinergic system (Sir Henry Dale and Professor Otto Loewi, Nobel Prize 1936), is
the natural product, (−)-physostigmine (15a). An alkaloid isolated from the seeds of the Calabar
bean, Physostigma venenosum,7–9 (−)-physostigmine (15a) has provided a template in the
development of several AD drugs, including rivastigmine (Novartis, Basel, Switzerland),
phenserine (National Institute on Aging, Baltimore, MD, and Axonyx, New York, NY),
eptylstigmine (Mediolanum, Milan, Italy) and the parent compound, itself, in a slow-release
formulation (Synapton, Forrest laboratories, St Louis, MO).3,10,11 Extensive structure-
activity relationships of this class of ChEIs indicates that (i) all derivatives of physostigmine
with anticholinesterase activity are levorotary, with a 3a-S configuration in their pyrroloindole
tricyclic ring system, and, (ii) selectivity between the two cholinesterase forms, acetyl- (AChE:
EC3.1.1.7) and butyrylcholinesterase (BChE: EC 3.1.1.8), is primarily correlated with the
structure of the N-substituted moiety of the carbamoyl side chain.10–12
An exception to the enantiomeric selectivity of physostigmine derivatives is the N1-nor series
of derivatives.13,14 (−)-Physovenine (20a), a congeneric alkaloid of physostigmine,9,10 also
lacks enantiomeric selectivity.10,15,16 The (+)-isomers of these two series of compounds,
interestingly, have unexplainable anticholinesterase activity.13–16 In our continuing effort to
design new and improved ChEIs, we recently successfully synthesized two novel series of bio-
active racemic carbamates with the tricyclic skeletons, furobenzofuran and
methanobenzodioxepine.17 Herein, we describe the synthesis and activity of their optically
pure enantiomers with the dual purpose of (i) developing new AD drug candidates and (ii)
utilizing them as tools to elucidate the molecular interactions required by the tricyclic skeleton
of this important class of ChEI to achieve enantio-selectivity within AChE and BChE.
RESULTS
Chemistry
The starting material, 5-hydroxy-3-methyl-3-methoxycarbonylmethylene-benzofuran-2-one
(1), was produced from C3-alkylation of the condensation product of 1,4-cyclohexandione and
pyruvic acid, according to a previously reported procedure.17 First, compound 1 was reacted
with (−)-menthyl chloroformate to provide a mixture of the stereoisomers of (3S) and (3R)-
menthylcarbonates of 5-hydroxy-3-methyl-3-methylacetate-benzofuran-2-one 2 and 3
(Scheme 1).
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Since it proved difficult to isolate stereoisomer 2 and 3 with chromatography, we separated
them by repeated crystallization. This was performed from hexane, at first, and then from
ethanol to eventually yield two separate crystals with different crystalline forms: needle (2)
and flaky (3) (Experimental Section).
The absolute configuration of the C-3 position was determined based on the known
configurations of C-19, C-21 and C-24 from compound 3 by X-ray crystallography. Figure 1
shows that compound 3 has a R configuration at its 3-position. As a consequence, compound
2 should possess a S configuration at its 3-position. The use of chiral HPLC to measure the
optical purity of compounds 2 and 3 proved unsuccessful. The hydrolysis of stereoisomer 2
and 3 provided (−)-enantiomer 4, [α]D26 −2.6° (C=0.62, CHCl3), and (+)-enantiomer 5,
[α]D27 +2.2° (C=0.45, CHCl3) (Scheme 1), respectively. The enantiomeric excesses value (ee
%) of each was measured by chiral HPLC analysis and reported in the Experimental Section
(Figure 2). Compounds 4 and 5 were, for practical purposes, optically pure. In the process of
reduction, the stereochemistry at the 3-position of compounds 2 and 3 was unchanged. Hence,
2 gave 6a (3aS-configuration) and 7a (5S-configuration); whereas, 3 gave 6b (3aR-
configuration) and 7b (5R-configuration). The probable mechanism underpinning this
reductive cyclization has recently been published.17, 18 In our recent prior research, we
reported that the reductive cyclization of (±)-5-hydroxy-3-methyl-3-methylaceta-
tebenzofuran-2-one by LiAlH4 gave tetrahydrofurobenzofuran and methanobenzodioxipene
in a yield of 10%.17 In the present report, the reductive lithium-aluminum complexes of
compound 2 and 3 were acidified by 1M HCl in anhydrous Et2O, instead of oxalic acid, to
elevate the yield to approximately 30% (Scheme 2).
Phenols 6a and 7a, as well as 6b and 7b were reacted with different isocyanates to give 6 pairs
of corresponding carbamates: 8a and 11a, 9a and 12a, 10a and 13a, as well as 8b and 11b,
9b and 12b, 10b and 13b, respectively. Thereafter, each of these pairs of compounds was
separated by preparative TLC, utilizing a procedure reported previously.17
The syntheses of carbamates of the physostigmine and physovenine series of analogues are
shown in Scheme 3. Compounds 15a and b, 17a, 18a, 20a and b, 22a and 23a are known
compounds.15,16 Compounds 16a and 21a were synthesized from compounds 14a and 19a,
which were obtained from natural physostigmine according to a known procedure.17
Compounds 17b, 18b, 22b and 23b were synthesized from (+)-3a(R)-eseroline (14b) and
(+)-3a(R)-physovenol (19b). These phenols, (14b) and (19b), were obtained by asymmetric
syntheses starting from N-methylphenetidine.14
X-ray Crystallography
The results of the X-ray studies of compound 3 are illustrated in Figure 1. The chirality of the
asymmetric center are as follows: C3-R, C19-R, C21-R and C24-S. The six-membered ring of
the menthyl moiety has a chair conformation; in contrast, the benzofuran system is flat.
Biological Evaluation
Table 1 shows the anticholinesterase activity of enantiomers 8–13, 15–18 and 20–23 against
freshly prepared human AChE and BChE, derived from erythrocytes and plasma, respectively.
The concentration of compound required to inhibit 50% enzyme activity (IC50 value) was
quantified by a modified Ellman technique,13–17, 19–21 and values for R-configuration versus
S-configuration are represented by the symbol R/S. A smaller IC50 is associated with a lower
Ki value and a higher affinity of inhibitor-enzyme binding.22–24 A R/S value of 1 is indicative
of similar inhibitory activity for the R- and S-configurations. For a R/S value >1, the compound
with a R-configuration has a lower potency than its enantiomer.
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With the sole exception of the compound pair, 17a and 17b, that possessed low and
approximately similar BChE inhibitory activity (R/S=0.6), all compounds with a S-
configuration proved to be more potent than their corresponding enantiomer (R/S > 1). This
was most evident in the physostigmine series, where AChE inhibitory activity was achieved
with a R/S value ≥ 353 and BChE inhibitory action was achieved with a R/S value ≥ 102. Hence,
in the physostigmine series, carbamates of (+)-physostigmine (15b, 17b, 18b) possess minimal
cholinergic activity, quite the opposite of their potent (−)-enantiomers.
In complete contrast with the physostigmine series, both enantiomers of the novel
tetrahydrofurobenzofuran (8a and b, 9a and b, 10a and b) and dihydrobenzodioxepine (11a
and b, 12a and b, 13a and b) series possessed potent anticholinesterase action for AChE, BChE
or both, with R/S values of ≤9.3. This activity is in accord with the congener, physosvenine
carbamates (20a and b, 21a and b, 22a and b, 23a and b) that are similarly active in both
enantiomeric forms with a preference for the S-configuration. As described, N-demethylation
of physostigmine (15a) minimizes the enantio-selectivity of this series,14 which suggests that
the N1-substitution of the tricyclic ring is a key determinant regarding enantio-selectivity.
Additionally, the development of members of the tetrahydrofurobenzofuran and
dihydrobenzodioxepine series to clinical development could be undertaken with either the
potent S- (−)-enantiomers or the racemates, whose synthesis would be far easier and cheaper
(avoiding optical resolution) and whose anticholinesterase activity is almost equal. A
comparison of Table 1 and Table 2, the latter defining the anticholinesterase activity of agents
of current and recent clinical interest against enzyme drawn from the same individual and
analyzed similarly, suggests that compounds 9a, 12a and 10a, 13a possess sufficient potency
and selectivity for AChE and BChE, respectively, to be of clinical interest.
In each of the four series of compounds detailed in Table 1, the differential selectivity for AChE
or BChE is determined by the structure of N-substituted moiety of the carbamate. Specifically,
the N-methyl carbamates provide minimal enzyme subtype selectivity. The N-ethyl carbamates
have a moderate BChE preference. The N-2’-methylphenylcarbamates have high AChE
selectivity and N-4’-isopropylphenylcarbamates reverse this and demonstrate a high BChE
preference. Of particular note, the AChE and BChE selectivities of the novel
tetrahydrofurobenzofuran and dihydrobenzodioxepine series are amongst the greatest found
of all ChEIs yet synthesized on the tricyclic backbone of physostigmine.
DISCUSSION
Molecular comparison by volume calculations
As all of the described carbamates possess close structural similarity as well as a similar
inhibitory mechanism, we can initially compare them by means of superimposition to further
elucidate the basis of their enantio-selectivity. This was undertaken for the four AChE potent
inhibitors with S-configuration carbamates (9a, 12a, 17a and 22a) by generating a ‘molecular
volume map’ of each molecule that corresponds to their van der Waals surface.25,26
As illustrated in Figure 3, for each compound, the relative positions of their two phenyl
moieties, on either side of the carbonyl group in their optimized conformation, were almost
identical – closely overlaying one another. These four compounds could be closely
superimposed, except for disparity in their tricyclic systems. The combined molecular volume
map of compounds 9a, 12a, 17a and 22a provides an ‘enzyme – excluded map’ (green area in
Figure 3), within which all active compounds should fit. The molecular volume of the R-2’-
methylphenyl carbamates, 9b, 12b, 17b and 22b, minus the enzyme – excluded volume
provides an ‘estimate volume’ that represents the additional volume generated by that of each
R-isomer (yellow meshed area within Figure 3).
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As shown in Table 3, the lowest estimate extra volume of compound 9b (7.1 Å3) corresponds
to the lowest enantio-selectivity (R/S = 1.8). The highest estimate extra volume (24.8 Å3) of
compound 17b corresponds to the highest enantio-selectivity (R/S = 551). Specifically, the
larger estimate extra volume of compound 17b (yellow meshed area in Figure 3) likely
seriously hinders the approach to and hence binding between the inhibitor and enzyme.
Molecular modeling studies were undertaken to aid elucidate how this additional estimate extra
volume hinders binding.
Molecular model of the transition state
The wide structural diversity of available ChEIs suggests that unlike types of inhibitors bind
with AChE in different ways via disparate yet specific interactions between compound and
enzyme.27–29 Most anticholinesterases, such as those in Table 2 as well as the potent non-
clinical tacrine-based triazoles and other hybrids, are cationic at physiological pH; whereas
some, including those of the present study and arisugacin, are not.30–32 Human
cholinesterases are large complex molecules composed of catalytic subunits that can clearly
accommodate a variety of specific binding interactions associated with these diverse inhibitors.
They contain up to 583 amino acids, a Mr of 70–80 kDa, and are variably glycosylated.29,33
Three-dimensional analyses of AChE and BChE, based on x-ray crystallography, have
provided structural information regarding the positioning of the catalytically important amino
acid residues within these proteins.34–41 In synopsis, three major binding domains have been
described within AChE and two within BChE in an internalized, primarily hydrophobic gorge
of some 20 Å length, but as narrow as 0.5 Å wide. Deepest within this gorge is a catalytic ‘acyl’
binding domain, which hydrolyses choline esters through electron transfer within a catalytic
triad, termed a ‘charge relay system. The triad includes a Ser200, the imidazole group of a
His440, and the carboxylic acid moiety of a Glu327 (TcAChE numbering). A ‘choline’ binding
domain resides midway along the gorge, and a ‘peripheral’ anionic site exists at the gorge
mouth for AChE but not BChE,30–41 and this latter site may be involved in the complexing
of AChE with amyloid-β peptide in the Alzheimer brain.42 Notably, the neurotoxicity
associated with Aβ-AChE complexes has been shown to be greater than that induced by the
Aβ peptide alone in both cell culture and animal experiments.39
On the basis of calculations and electro-optical measurements, it has been suggested that
electrostatic charges associated with seven negatively charged amino acids residues close to
the entrance of the gorge trap and steer charged ligands into its mouth.43,44 In the case of
ACh, the quaternary choline moiety interacts with Trp84 of TcAChE and, to a lesser extent,
with Phe330 within the choline binding domain. This orientates the compound to allow the
approach and nucleophilic attack of the catalytic triad on its carbonyl group. A quaternary
transition state between Ser200 and ACh momentarily exists that then rapidly collapses into an
acylated-enzyme intermediate and released choline. Thereafter, prompt hydrolysis of the
acetylester reactivates the enzyme to allow efficient cleavage of as many as 104 ACh molecules
per second.37,38 (−)-Physostigmine (15a) and analogues interact similarly with the same two
binding domains. However, nucleophilic attack of its carbonyl moiety results in a transient (−)-
physostigmine-AChE intermediate, in a tetrahedral conformation, that then swiftly collapses
to a carbamylated drug-enzyme complex that is dramatically more stable than the acetyl
enzyme one associated with ACh; enzyme inhibition occurs consequent to the slow rate of
enzyme decarbamylation. The inhibition process, hence, involves AChE-catalyzed hydrolyses
of inhibitors.37,38 In such a chemical reaction, the highest energy transition state controls the
overall rate of the reaction. A catalytic enzyme can lower this energy barrier by specific
interaction with the inhibitor in the transition state (24 – 25).45 (Scheme 4). As shown in Table
1, each of the eight different carbamates with a same N-substituted side chain (e.g., 8 a and
b, 11 a and b, 16 a and b, 21 a and b) should generate identical carbamylated enzyme structures
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after their reaction with either AChE or BChE. Hence their different IC50 values should be
related to their affinities and rates of carbamylation, and not to decarbamylation – which would
impact the time-dependence of the inhibition associated with each. As a consequence we can
focus on carbamylation due to the short time frame of our biological studies.
A better insight into the molecular interactions of the enzyme and inhibitor can be obtained at
the transition state. Whereas it is not currently possible to produce a crystal structure of an
enzyme complexed with its substrate in the transition state, due to the short transition state
lifetime versus the time required for X-ray data collection, one can exploit the high affinity of
transition state analogues. In this regard, the analogue, m-(N,N,N-trimethylammonio)-2,2,2-
trifluoroacetophenone (TMTFA), possessing a low Ki (15 fM) for inhibition of TcAChE,46
was utilized to aid model the interaction of our compounds within the active site of AChE.
Prior investigation of the X-ray crystallographic structure of TcAChE complexed with the
known physostigmine analogue, MF268 (8-(cis-2,6-dimethylmorpholino)
octylcarbamoyleseroline), demonstrated the presence of a covalent bond between the carbonyl
carbon and γ-O of Ser200, and that the N-substituted side chain of the carbamoyl moiety is
located inside the acyl-binding pocket and extends to the rim of the active site gorge.47,48 The
X-ray crystallographic transition state analogue structure of TcAChE-TMTFA (code 1AMN)
was obtained from the RCSB protein databank. After extraction of TMTFA, the (−)-(3aS)-
N-2’-methylphenylcarbamoyl phenol of furobenzofuran (9a) was docked, in accord with
knowledge gained from the binding of MF268.47,48
As shown in Figure 4, six hydrogen bonds are apparent within the model (yellow lines): the
NH of Gly118, Gly119 and Ala201 with the oxygen of the ligand carbonyl, the γ-O of Ser200
with a single H, the hydrogen with N of His440, and the NH of His440 with the oxygen of
Glu327. Together with the covalent bond of the γ-O of Ser200 with the C of the ligand’s carbonyl
group, the illustrated hydrogen bonds comprise an acylation site. This site is considered as a
crucial part of the transition state. A transition state model was developed by (i) keeping the
acylation site intact (by constraining the relative distances between the described atoms) and,
(ii), minimizing the complex energy, after automatic adjustment of the conformation of the
remaining complex.
This model resembles a ‘beam balance’. The central supporting point is a covalent bond
between the γ-O of Ser200 and the C of the ligand’s carbonyl group. The π-π interaction system
between the N-phenyl group of carbamate (9a) and the phenyl group of Phe288 of the enzyme
comprises one side of this balance. The π-π or lipophilic (C–H⋯π) interaction system of the
furobenzofuran moiety of compound 9a and the indole system of Trp84 of the enzyme forms
the other side of the balance. Such C–H⋯π interactions have been observed in the x-ray crystal
structure of other neutral molecules with TcAChE.49 Any change on either side of this balance
may adversely affect the formation of the transition state. Utilizing this model, we can revisit
the basis of enantio-selectivity and enzyme subtype selectivity.
Enantio-selectivity
As shown by molecular volume calculations (Figure 3, Table 3), for all carbamates with a R-
configuration, with the exception of the physostigmine series, their molecular volumes are not
greatly different. This would support the lipophilic interaction between the tricyclic ring system
of the ligands and the indole system of Trp84 of the enzyme. Hence, all of these compounds
retain substantial anticholinesterase activity compared to their S-isomers.
The only exception involves R-configuration compounds having a N1-methyl group (the
physostigmine series). The model predicts that the N1-methyl group will become inserted
between the tricyclic ring system and the indole system of Trp84. The lipophilic interaction
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will consequently disappear, and a transition state between ligand and enzyme complex would
not be readily formed without this lipophilic interaction. As a result, the (+)-physostigmine
analogues 15b, 17b and 18b would be predicted to possess a poor AChE and BChE inhibitory
action, in accord with their measured poor ChEI activity.
Enzyme subtype selectivity
The acyl-binding pockets within AChE and BChE differ from one another in size and shape.
The pockets can be differentiated on the basis of two amino acid residues located at the bottom
of the acyl-loop. These residues are aromatic in AChE (Phe288 and Phe290) but aliphatic in
BChE (Leu286 and Val288).33,35,37,38,46 The latter pocket, hence, is slightly larger due to
the smaller protruding side chains associated with Leu and Val.12.
Our previous studies have shown that the conformational energy barrier of the N-phenyl group
of compound 17a and its analogues, rotated around C1’-N bond, is correlated to the IC50 of
AChE. A higher energy barrier is associated with a lower inhibitory activity (a larger IC50);
although, inexplicably, the energy barrier is as low as 0–0.7 kcal/mol. 21
According to the described transition state model (Figure 4), the π-π interaction system between
the N-phenyl group of the carbamate (17a) and the phenyl group of Phe288 of the enzyme
comprises one side of this balance. Rotation of the N-phenyl group will decrease this π-π
interaction and directly influence the stability of the transition state; consequently lowering the
affinity between ligand and enzyme. 21
Utilizing the same model, we can now propose a basis for the cholinesterase subtype selectivity
of the different carbamates moieties. (i) The small methyl group of N-methylcarbamates has
almost no lipophilic interaction with residues of the acyl pocket, it thus has little influence on
this balance and hence there is minimal subtype selectivity between AChE and BChE for N-
methyl carbamates of all series. (ii) The ethyl group of N-ethylcarbamates, likewise, has
relatively meager, but, nevertheless, greater lipophilic interaction than N-methylcarbamates.
The direction of this interaction is more favorable to form a stable transition state within BChE
than AChE. Hence, all of N-ethyl carbamates possess a moderate BChE selectivity. (iii) The
phenyl group of N-phenylcarbamates provides a significant lipophilic interaction with the
aromatic ring of Phe288. This interaction together with the lipophilic interaction between the
tricyclic ring system and indol moiety of Trp84 provides a highly stable transition state. Thus,
all N-phenyl and N-methylphenyl carbamates possess potent AChE activity. Within BChE,
however, Phe288 is replaced by an amino acid with an aliphatic residue. A similar π-π
interaction cannot be formed and leads to an unfavorable stability in the transition state, and
consequent weak BChE inhibitory activity. N-phenyl and N-methylphenyl carbamates hence
have high AChE selectivity. Finally, (iv) the 4’-isopropylphenyl moiety of N-4’-
isopropylphenyl carbamates cannot achieve a π-π interaction within the acyl-binding pocket
of AChE consequent to the bulk and hindering action of the isopropyl moiety. Within BChE,
however, the lipophilic interaction of the isopropylphenyl group with residues of BChE in its
larger acyl-binding pocket is favored (consequent to replacement of AChE Phe288 and
Phe290 by Val and Leu), which stabilizes the transition state. Thus all of the N-4’-
isopropylphenyl carbamate series have a potent and selective BChE inhibitory action.
In accord with this, one of the most potent and selective BChE inhibitors in the physostigmine
series, (−)-N1-phenethylnorcymserine (26) (IC50: AChE >30,000 nM, BChE 6.0±1.0 nM,
selectivity >5000-fold BChE) (Fig. 5),19 similarly can fit within the elongated acyl binding
pocket associated with BChE. However, as the N1-phenethyl moiety is directed outside the
lipophilic interaction system, activity is not perturbed. Indeed, it is augmented, likely, as a
consequence of hydrophobic interactions close to the gorge mouth. Interestingly, the elongated
(−)-4’-benzoxyphenyl carbamate of physostigmine, 27 (Fig. 5),50 that lacks a hindered 4’-
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isopropyl group, can maintain the π-π interaction associated with potent AChE binding, but
make use of the larger acyl pocket associated with BChE to achieve BChE inhibitory potency
(IC50: AChE 58±4 nM, BChE 7.0±1.0 nM, selectivity 7-fold BChE). 50
In synopsis, we report a new enantiomeric synthesis, through classical resolution, of two novel
series of potent anticholinesterases: the O-carbamoyl phenols of furobenzofuran and
benzodioxepine. These two series provide candidates to selectively inhibit either AChE or
BChE and, additionally, include some that possess neurotrophic actions.17 Such actions may
or may not be cholinergically mediated and provide this class of drugs actions beyond those
that are classically considered to be only symptomatic.51,52 Carbamates of these novel series
are sufficiently active to be of potential clinical interest, comparing favorably with the
inhibitory action of approved and recent ChEIs (Table 2, Figure 6), and could be developed
either as their potent S-enantiomers or as their synthetically cheaper racemates. In addition,
their enzyme subtype selectivity compare favorably with the classical selective
anticholinesterases, BW284c51 and iso-OMPA. Based on the described molecular volume
calculations and known X-ray structure of a transition state complex of TcAChE-TMTFA, we
have developed a beam balance-like transition state model of the TcAChE-N-phenylcarbamate
complex. Using this model, we can now propose a basis to account for the enantio-selectivity
of physostigmine and its congeners.
Experimental Section
Chemistry
Melting points (uncorrected) were measured with a Fisher-Johns apparatus; 1H NMR and 13C
NMR were recorded on a Bruker (Bellevica, MA) AC-300 spectrometer; MS (m/z) were
recorded on a Hewlett-Packard 5973 GC-MS (CI); HRMS were performed by the UCR Mass
Spectrometry Facility, Department of Chemistry, University of California; Optical rotations
were measured by JASCO, Model DIP-370 (Japan, Spectroscopic Co., LTD.); Elemental
analyses were performed by Atlantic Microlab, Inc.; The ee% value of optically active
compounds was determined by HPLC analyses using a HP1100 instrument and a chiral column
(ChiraDex® 5µm) (Agilent Technology), mobile phase MeOH/H2O = 45/55, elution rate 0.5
ml/min., UVD 254 nm – all at room temperature. All reactions involving non-aqueous solutions
were performed under an inert atmosphere.
(3S) And (3R)-Menthyl carbonates of 5-hydroxy-3-methyl-3-methylacetate-benzofuran-2-one
(2) and (3)
Under a nitrogen atmosphere, a solution of 5-hydroxy-3-methyl-3-
methoxycarbonylmethylenebenzofuran-2-one (1) (116mg, 0.491mmol) in 0.06 mL of
triethylamine and 1.5mL of benzene was dropwise added into (−)-menthyl chloroformate
(118mg, 0.539mmol) at room temperature. The mixture was stirred for 1.5 hours at the same
temperature. The crude product was subjected to chromatography on silica gel (EtOAc/
Hexane=1/3) to give 156.5 mg of white crystalline product, yield 76.2%: 1H-NMR (CDCl3) δ
7.20-7.02 (m, 3H, Ar-H), 4.68-4.52 (m, 1H, CH-OC=O), 3.53 (s, 3H, CH3O), 3.10, 2.96 (AB,
Jgem=17.6Hz, 2H, C3-CH2COO), 2.21-2.11 (m, 1H, CH-iPr), 2.10-1.98 (m, 1H, CHMe),
1.80-1.65 (m, 1H, CHMe2), 1.51 (s, 3H, C3-CH3), 1.59-1.41 (m, 2H, CH2COC=O), 1.26-0.80
(m, 4H, CH2CH2), 0.97 (d, 6H, CH3CCH3) and 0.85 (d, 3H, CH3CCCOC=O) ppm; CI-MS
(CH4), m/z: 419(MH+), 418, 417, 371, 237, 181, 153 and 109; HR-MS m/z: Calcd for
C23H34NO7(MNH4 +): 436.2335; Found: 436.2326. The above white crystal product was,
thereafter, recrystallized from both hexane and ethanol, separately, several times, until the
optical rotations and melting points of the two different isolated crystalline forms did not
change. One, a needle crystalline form, was product 2: m.p. 106.8–107.4°C; [α]D 25-60.8°
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(c=0.53,CHCl3). Anal. (C23H30O7) C, H. The other, a flaky crystalline form, was product 3:
m.p.148.0–148.8°C; [α]D26-19.7 °(c=0.74,CHCl3). Anal. (C23H30O7) C, H.
(−)-(3S)-5-Hydroxy-3-methyl-3-methylacetate-benzofuran-2-one (4)
Under a nitrogen atmosphere, a mixture of reactant 2 (0.493g, 1.178 mmol) and sodium
hydroxide (0.2g, 5.0 mmol) in 18 mL of methanol was stirred for 1.5 hours at room temperature.
It was then neutralized with 1N HCl. After removing solvent, the residue was chromatographed
on silica gel (CH2Cl2/MeOH=10/1) to give 168.2 mg of product 4, yield 60.4%: m.p. 157.0–
159.0 °C; [α]D26 −2.6 °(c=0.62,CHCl3); ee%=100% (HPLC); 1H-NMR (CDCl3) δ 6.92-6.61
(m, 3H, Ar-H), 5.07 (s, 1H, OH), 3.44 (s, 3H, OCH3), 3.02, 2.84 (AB, Jgem=18.0Hz, 2H, C3-
CH2C=O) and 1.41(s, 3H, C3-CH3) ppm; CI-MS (CH4), m/z: 237(MH+), 205, 177 and 163.
(+)-(3R)-5-Hydroxy-3-methyl-3-methylacetate-benzofuran-2-one (5)
Compound 5 was prepared as described above, yield 66.0%: m.p. 156.0–158.6 °C; [α]D27+2.2
°(c=0.45,CHCl3); ee%=100%. The 1HNMR and CI-MS (CH4) are the same as that of
compound 4.
(3aS)-5-Hydroxy-3a-methyl-2, 3,3a, 8a-tetrahydrofuro[2,3-b] benzofuran (6a) and (5S)-7-
Hydroxy-5-methyl-4, 5-dihydro-2, 5-methano-1, 3-benzodioxepine (7a)
Under a nitrogen atmosphere, a solution of compound 2 (177 mg, 0.423mmol) in 2mL of ether
was dropwise added to lithium aluminum hydride (32 mg, 0.843 mmol) in ether at 0°C. The
mixture, after stirring at 0°C for 0.5h, was stirred for another one hour at room temperature.
Thereafter, 1M HCl ether solution and was to provide a mixture of pH 3–4, which then was
stirred for 0.5 hour at room temperature. Next, the mixture was filtered and the filtrate was
concentrated. The residue was subjected to chromatography on silica gel (EtOAc/Hexane=1/3)
to give 24.4 mg of a mixture of compounds 6a and 7a. The GC-CI-MS and 1H-NMR of this
mixture were the same as that of the racemic17 and showed an approximate 1:1 molar ratio of
(3aS)-5-hydroxy-3a-methyl-2, 3,3a, 8a-tetrahydrofuro[2,3-b] benzofuran (6a) and (5S)-7-
hydroxy-5-methyl-4, 5-dihydro-2, 5-methano-1, 3-benzodioxepine (7a). The yields were 30%
and the compounds were directly used as starting material for the next reactions.
(3aR)-5-Hydroxy-3a-methyl-2, 3,3a, 8a-tetrahydrofuro[2,3-b] benzofuran (6b) and (5R)-7-
Hydroxy-5-methyl-4, 5-dihydro-2, 5-methano-1, 3-benzodioxepine (7b)
Compounds 6b and 7b were prepared from compound 3, according to the procedure described
for compounds 6a and 7a.
(−)-(3aS)-3a-Methyl-2, 3,3a, 8a-tetrahydrofuro[2,3-b] benzofuran-5yl N-ethyl carbamate (8a)
and (−)-(5S)-5-Methyl-4, 5-dihydro-2, 5-methano-1, 3-benzodioxepin-7yl N-ethyl carbamate
(11a)
Under a nitrogen atmosphere, two small pieces of sodium (about 1 mg) were added into a
solution of mixture of 6a and 7a (24.4 mg, 0.127 mmol) in 5 mL of anhydrous ether at room
temperature. This mixture was then stirred for 2 minutes, and ethyl isocyanate (30.1 µL, 0.381
mmol) was next added to the reaction mixture in one portion. An hour into the reaction at room
temperature, 1.4 mL of water was added and the ether layer was separated. After drying over
sodium sulphate and filtering, the filtrate was evaporated to remove solvent. The residue was
chromatographed on silica gel plate (EtOAc/Hexane =1/3) to afford products 8a and 11a.
Product 8a (11.6 mg, 69.7%): [α]D26 −92.2° (c=0.09, CHCl3); e.e.100%; 1H-NMR (CDCl3) δ
6.87-6.60 (m, 3H, Ar-H), 5.77 (s, 1H, C8a-H), 4.89 (s, br, 1H, NH), 4.06-3.56 (m, 2H, C2-H),
3.23 (m, 2H, C5-CH2NHCOO), 2.13-1.91 (m, 2H, C3-H), 1.47 (s, 3H, C3a-CH3) and 1.14 (t,
3H, C5-CH3CH2NHCOO) ppm; CI-MS (CH4), m/z: 264 (MH+), 193, 175 and 72. Anal.
(C14H17N O4) N, H; C: Calcd. 63.87; Found 63.14. Product 11a (14.1 mg, 84.6%): [α]D25
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−10.0°(c=0.12, CHCl3), e.e.100%. 1H-NMR (CDCl3) δ 6.82-6,67(m, 3H, Ar-H), 5.69 (d,
J=1.80Hz, 1H, C2-H), 4.88 (s, br, 1H, C7-NHCOO), 4.17, 3.70 (AB, Jgem=7.20Hz, 2H, C4-
H), 3.22 (m, 2H, C-7CH2NHCOO), 2.19-1.19 (m, 2H, C10-H), 1.41 (s, 3H, C5-CH3) and 1.16
(t, 3H, C7-CH3CH2NHCOO) ppm; CI-MS (CH4), m/z: 264 (MH+), 246, 220, 193, 175, 149
and 72. Anal. (C14H17N O4) C, H; N: Calcd. 5.32; Found 4.91.
(+)-(3aR)-3a-Methyl-2, 3,3a, 8a-Tetrahydrofuro[2,3-b] benzofuran-5yl N-ethyl carbamate (8b)
and (+)-(5R)-5-Methyl-4, 5-dihydro-2, 5-methano-1, 3-benzodioxepin-7yl N-ethyl carbamate
(11b)
Under a nitrogen atmosphere, two small pieces of sodium (about 1 mg) were added into a
solution of mixture of 6b and 7b (26 mg, 0.135 mmol) in 5 mL of anhydrous ether at room
temperature. The mixture was stirred for 2 minutes and, thereafter, ethyl isocyanate (32.8 µL,
0.408 mmol) was added to the reaction mixture in one portion. The reaction was continued for
an hour at room temperature, 4.0 mL of water was then added and the ether layer was separated.
After drying over sodium sulphate and filtering, the filtrate was evaporated to remove solvent.
Thereafter, the residue was subjected to chromatography on silica gel plate (EtOAc/Hexane =
1/3) to afford products 8b and 11b. Product 8b (14.8 mg, 83.1%): [α]D26 +92.5° (c=0.08,
CHCl3); e.e. 100%; 1H-NMR (CDCl3) δ 6.87-6.60 (m, 3H, Ar-H), 5.77 (s, 1H, C8a-H), 4.89
(s, br, 1H, NH), 4.06-3.56 (m, 2H, C2-H), 3.23 (m, 2H, C5-CH2NHCOO), 2.13-1.91 (m, 2H,
C3-H), 1.47 (s, 3H, C3a-CH3) and 1.14 (t, 3H, C5-CH3CH2NHCOO) ppm; CI-MS (CH4), m/
z: 264 (MH+), 193, 175 and 72. Anal. (C14H17N O4) C, H; N: Calcd. 5.32; Found 4.78. Product
11b (10.4 mg, 58.4%): [α]D26 +10.0° (c=0.05, CHCl3); e.e. 100%. 1H-NMR (CDCl3) δ
6.82-6,67(m, 3H, Ar-H), 5.69 (d, J=1.80Hz, 1H, C2-H), 4.88 (s, br, 1H, C7-NHCOO), 4.17,
3.70 (AB, Jgem=7.20Hz, 2H, C4-H), 3.22 (m, 2H, C-7CH2NHCOO), 2.19-1.19 (m, 2H, C10-
H), 1.41 (s, 3H, C5-CH3) and 1.16 (t, 3H, C7-CH3CH2NHCOO) ppm; CI-MS (CH4), m/z: 264
(MH+), 246, 220, 193, 175, 149 and 72. Anal. (C14H17N O4) C, H, N.
(−)-(3aS)-3a-Methyl-2, 3,3a, 8a-Tetrahydrofuro[2,3-b] benzofuran-5yl N-o-tolyl carbamate (9a)
and (+)-(5S)-5-Methyl-4, 5-dihydro-2, 5-methano-1, 3-benzodioxepin-7yl N-o-tolyl carbamate
(12a)
Under a nitrogen atmosphere, two small pieces of sodium (about 1 mg) were added into a
solution of mixture of 6a and 7a (27.9 mg, 0.145 mmol) in 5 mL of anhydrous ether at room
temperature. The mixture was stirred for 2 minutes, and then o-tolyl isocyanate (18.9 µL, 0.149
mmol) was added to the mixture in one portion. The reaction was continued for 35 minutes at
room temperature, 4 mL of water then was added and the ether layer was separated. After
drying over sodium sulphate and filtering, the filtrate was evaporated to remove solvent. The
residue was chromatographed on silica gel plate (EtOAc/Hexane = 1/3) to afford products
9a and 12a. Product 9a (15.6 mg, 66.1%): [α]D27−103.0° (c=0.10, CHCl3); e.e.100%; 1H-NMR
(CDCl3) δ 7.84 (s, br, 1H, NH), 7.32-6.70 (m, 7H, Ar-H), 5.89 (s, 1H, C8a-H), 4.18-3.68 (m,
2H, C2-H), 2.39-2.05 (m, 2H, C3-H), 2.31 (s, 3H, Ar-CH3) and 1.56 (s, 3H, C3a-CH3) ppm;
CI-MS (CH4), m/z: 326 (MH+). Anal. (C19H19N O4) H; Calcd. C, 70.14; N, 4.25; Found C,
69.18; N,3.71. Product 12a (15.0 mg, 63.5%): [α]D27 +30.4° (c=0.135, CHCl3), e.e.
100%; 1H-NMR (CDCl3) δ 7.87 (s, br, 1H, C7-NHCOO), 7.33-6.70 (m, 7H, Ar-H), 5.79 (d,
J=1.80Hz, 1H, C2-H), 4.22, 3.79 (AB, Jgem=6.84Hz, 2H, C4-H), 2.37-2.01 (m, 2H, C10-H),
2.31 (s, 3H, Ar-CH3) and 1.51 (s, 3H, C5-CH3) ppm; CI-MS (CH4), m/z: 326 (MH+). Anal.
(C19H19N O4) C; H: Calcd. 5.89; Found 6.36; N: Calcd. 4.31; Found 3.57.
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(+)-(3aR)-3a-Methyl-2, 3,3a, 8a-Tetrahydrofuro[2,3-b] benzofuran-5yl N-o-tolyl carbamate (9b)
and (−)-(5R)-5-Methyl-4, 5-dihydro-2, 5-methano-1, 3-benzodioxepin-7yl N-o-tolyl carbamate
(12b)
Under a nitrogen atmosphere, two small pieces of sodium (about 1 mg) were added into a
solution of mixture of 6b and 7b (18 mg, 0.09 mmol) in 5 mL of anhydrous ether at room
temperature. The mixture was stirred for 2 minutes, and then o-tolyl isocyanate (18.3 µL, 0.145
mmol) was added in one portion. The reaction was continued for a further 35 minutes at room
temperature, 4 mL of water then was added and the ether layer was separated. After drying
over sodium sulphate and filtering, the filtrate was evaporated to remove solvent. The residue
was chromatographed on silica gel plate (EtOAc/Hexane=1/3) to afford products 9b and
12b. Product 9b (11.0 mg, 74.9%), [α]D26+104.2° (c=0.095, CHCl3); e.e. 100%; 1H-NMR
(CDCl3) δ 7.84 (s, br, 1H, NH), 7.32-6.70 (m, 7H, Ar-H), 5.89 (s, 1H, C8a-H), 4.18-3.68 (m,
2H, C2-H), 2.39-2.05 (m, 2H, C3-H), 2.31 (s, 3H, Ar-CH3) and 1.56 (s, 3H, C3a-CH3) ppm;
CI-MS (CH4), m/z: 326 (MH+). Anal. (C19H19N O4) C, H; N: Calcd. 4.31; Found 3.78. Product
12b (9.5 mg, 64.4%), [α]D27−29.0° (c=0.10, CHCl3); e.e. 100%; 1H-NMR (CDCl3) δ 7.87 (s,
br, 1H, C7-NHCOO), 7.33-6.70 (m, 7H, Ar-H), 5.79 (d, J=1.80Hz, 1H, C2-H), 4.22, 3.79 (AB,
Jgem=6.84Hz, 2H, C4-H), 2.37-2.01 (m, 2H, C10-H), 2.31 (s, 3H, Ar-CH3) and 1.51 (s, 3H,
C5-CH3) ppm; CI-MS (CH4), m/z: 326 (MH+). Anal. (C19H19N O4) N; Calcd. C, 70.14; N,
5.89; Found C, 69.49; N, 5.46.
(−)-(3aS)-3a-Methyl-2, 3,3a, 8a-Tetrahydrofuro[2,3-b] benzofuran-5yl N-p-isopropylphenyl
carbamate (10a) and (+)-(5S)-5-Methyl-4, 5-dihydro-2, 5-methano-1, 3-benzodioxepin-7yl N-
p-isopropylphenyl carbamate (13a)
Under a nitrogen atmosphere, two small pieces of sodium (about 1 mg) were added into a
solution of mixture of 6a and 7a (16 mg, 0.083 mmol) in 5 mL of anhydrous ether at room
temperature. The mixture was stirred for 2 minutes and p-isopropylphenyl isocyanate (14 µL,
0.086 mmol) was added to the mixture of 6a and 7a in one portion. The reaction was continued
for an additional 45 minutes at room temperature; thereafter, 4 mL of water was added and the
ether layer separated. After drying over sodium sulphate and filtering, the filtrate was
evaporated to remove solvent. The residue was chromatographed on silica gel plate (EtOAc/
Hexane = 1/3) to afford products 10a and 13a. Product 10a (8 mg, 54.4%): [α]D26−91.4°
(c=0.35, CHCl3); e.e.100%; 1H-NMR (CDCl3) δ 7.31-6.71 (m, 8H, Ar-H, HNCOO), 5.80 (s,
1H, C8a-H), 4.09-3.59 (m, 2H, C2-H), 2.82 (septet, J=5.24Hz, 1H, CHMe2), 2.19-1.96 (m,
2H, C3-H), 1.49 (s, 3H, C3a-CH3) and 1.18 (d, J=5.24Hz, 6H, CH3CCH3) ppm; CI-MS
(CH4), m/z: 354 (MH+). Anal. (C21H23N O4) H; Calcd. C, 71.37; N, 3.94; Found C, 70.86; N,
3.30. Product 13a (9 mg, 61.2%): [α]D26 +50.0° (c=0.2, CHCl3); e.e.100%; 1H-NMR
(CDCl3) δ 7.30-6.72 (m, 8H, Ar-H, HNCOO), 5.71 (d, J=1.80Hz, 1H, C2-H), 4.17, 3.70 (AB,
Jgem=5.40Hz, 2H, C4-H), 2.81 (septet, J=5.22 Hz, 1H, CHMe2), 2.19-1.94 (m, 2H, C10-H),
1.48 (s, 3H, C5-CH3) and 1.19 (d, J=5.22Hz, 6H, CH3CCH3) ppm; CI-MS (CH4), m/z: 354
(MH+). Anal. (C21H23N O4) C, H; N: Calcd. 3.96; Found 4.56.
(+)-(3aR)-3a-Methyl-2, 3,3a, 8a-Tetrahydrofuro[2,3-b] benzofuran-5yl N-p-isopropylphenyl
carbamate (10b) and (−)-(5R)-5-Methyl-4, 5-dihydro-2, 5-methano-1, 3-benzodioxepin-7yl N-
p-isopropylphenyl carbamate (13b)
Under a nitrogen atmosphere, two small pieces of sodium (approx.1 mg) were added into a
solution of mixture of 6b and 7b (18 mg, 0.094 mmol) in 5 mL of anhydrous ether at room
temperature. The mixture was stirred for 2 minutes, and then p-isopropylphenyl isocyanate
(14.6 µL, 0.096 mmol) was added in one portion. The reaction was continued for a further 45
minutes at room temperature, and then 4 mL of water was added and the ether layer separated.
After drying over sodium sulphate and filtering, filtrate was evaporated to remove solvent. The
residue was chromatographed on silica gel plate (EtOAc/Hexane = 1/3) to afford products
Luo et al. Page 11













10b and 13b. Product 10b (13.7 mg, 82.1%): [α]D27+91.4° (c=0.14, CHCl3); e.e. 100%; 1H-
NMR (CDCl3) δ 7.31-6.71 (m, 8H, Ar-H, HNCOO), 5.80 (s, 1H, C8a-H), 4.09-3.59 (m, 2H,
C2-H), 2.82 (septet, J=5.24Hz, 1H, CHMe2), 2.19-1.96 (m, 2H, C3-H), 1.49 (s, 3H, C3a-
CH3) and 1.18 (d, J=5.24Hz, 6H, CH3CCH3) ppm; CI-MS (CH4), m/z: 354 (MH+). Anal.
(C21H23N O4.1/8H2O) C, H, N. Product 13b (10.1 mg, 60.4%): [α]D27−48.0° (c=0.1,
CHCl3); e.e. 100%; 1H-NMR (CDCl3) δ 7.30-6.72 (m, 8H, Ar-H, HNCOO), 5.72 (d, J=1.80Hz,
1H, C2-H), 4.17, 3.70 (AB, Jgem=5.40 Hz, 2H, C4-H), 2.81 (septet, J=5.22 Hz, 1H, CHMe2),
2.19-1.94 (m, 2H, C10-H), 1.48 (s, 3H, C5-CH3) and 1.19 (d, J=5.22Hz, 6H,CH3CCH3) ppm;
CI-MS (CH4), m/z: 354 (MH+). Anal. (C21H23N O4) H, N; C: Calcd. C 71.37; Found 70.75.
(+)-(3aR)-1,3a, 8-Trimethyl-1, 2,3,3a, 8,8a-hexahydropyrrolo[2,3-b] indol-5ol (14b)
Compound 14b was synthesized, according to the procedure for its enantiomer, from N-
methylphenetidine.14
(+)-(3aR)-1,3a, 8-Trimethyl-1, 2,3,3a, 8,8a-hexahydropyrrolo[2,3-b] indol-5yl N- (2’-
methylphenyl) carbamate (17b)
Compound 17b was made, according to the procedure for its antipode, from o-tolyl isocyanate
and (+)-eseroline: 21 [α]D26 +68.2 °(c=0.2, CHCl3); 1H NMR and MS were the same as
reported for its enantiomer.21 Anal. (C21H25N3 O2) H; Calcd. C, 71.70; N, 11.95; Found C,
70.08; N, 11.45.
(+)-(3aR)- 1, 3a, 8-Trimethyl-1, 2,3,3a, 8,8a-hexahydropyrrolo[2,3-b] indol-5yl N- (4’-
isopropylphenyl) carbamate (18b)
Compound 18b was synthesized, according to the procedure for its antipode, from p-
isopropylphenyl isocyanate and (+)-eseroline:21 [α]D26+67.5 °(c=0.2, CHCl3); 1H NMR and
MS were the same as reported for its enantiomer.21 Anal. (C23H29N3 O2) H, N; C: Calcd.
72.79; Found 71.70.
(+)-(3aR)-3a, 8-Dimethyl-2, 3,3a, 8a-tetrahydrofuro[2,3-b] indol-5-ol (19b)
Compound 19b made according to the procedure for synthesis of its enantiomer.14, 17
(+)-(3aR)-3a, 8-Dimethyl-2, 3,3a, 8a-tetrahydrofuro[2,3-b] indol-5-yl N- (2’-methylphenyl)
carbamate (22b)
Compound 22b was synthesized, according to the procedure for its antipode, from o-tolyl
isocyanate and (+)-eseroline: 21 [α]D26+27.5 °(c=0.2, CHCl3); 1H NMR and MS were the same
as reported for its enantiomer.20 Anal. (C20H22N2 O3) C, H; N: Calcd. 8.28; Found 7.84
(+)-(3aR)-3a, 8-Dimethyl-2, 3,3a, 8a-tetrahydrofuro[2,3-b] indol-5-yl N- (4’-isopropylphenyl)
carbamate (23b)
Compound 23b was made, according to the procedure for its antipode, from p-isopropylphenyl
isocyanate and (+)-eseroline: 16 [α]D26 +32.0 °(c=0.2, CHCl3); 1H NMR and MS were the
same as reported for its enantiomer.17 Anal. (C22H26N2 O3) C, H; N: Calcd. 7.64; Found 7.13.
X-ray Crystallography
A clear colorless crystal of dimensions 0.30 × 0.23 × 0.12 mm2 was mounted on glass fiber
using a small amount of Epoxy. Data were collected on a Bruker three-circle platform
diffractometer equipped with a SMART 6000 CCD detector. The crystals were irradiated using
a rotating anode CuKα source (λ = 1.54178) with incident beam Göbel mirrors. Data collection
was performed and the unit cell was initially refined using SMART[v5.625]. 53(a) Data
Reduction was performed using SAINT [v6.36A] 53(b) and XPREP [v6.12]. 53(c) Corrections
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were applied for Lorentz, polarization, and absorption effects using SADABS [v2.03].53(d)
The structure was solved and refined with the aid of the programs in the SHELXTL-plus [v6.10]
system of programs. 53(e) The full-matrix least-squares refinement on F2 included atomic
coordinates and anisotropic thermal parameters for all non-H atoms. The H atoms were
included using a riding model. The absolute configuration of C3 was established by making
reference to unchanging chiral centers (C19, C21, and C24) in the synthetic procedure, with a
resulting Flack parameter of −0.3(2). 53(f) The X-ray data of compound 3 also can be found
at the Cambridge Crystallographic Data Center (CCDC), <http://www.ccdc.cam.ac.uk/ >. The
reference number of this crystal is 285734.
Quantitation of anticholinesterase activity
The action of enantiomers 8–13 and compounds 17b, 18b, 22b and 23b to inhibit the ability
of freshly prepared human AChE and BChE to enzymatically degrade their respective specific
substrates, acetyl-(β-methyl)thiocholine and s-butyrylthiocholine (0.5 mmol/L) (Sigma
Chemical Co., St. Lois, MO), was quantified.13–17, 19–21 Samples of AChE and BChE were
derived from freshly collected human whole red blood cells and plasma, respectively.
Compounds were dissolved in Tween 80/EtOH 3:1 (v:v; <150 µL total volume) and were
diluted in 0.1 M Na3P04 buffer (pH 8.0) in half-log concentrations to provide a final
concentration range that spanned 0.3 nM to 30 uM. Tween 80/EtOH was diluted to in excess
of 1 in 5000. No inhibitory action on either AChE or BChE was detected in separate
experiments where the ChEI activity of the known compound 15a was quantified in excess
and without Tween 80/EtOH.
For the preparation of BChE, freshly collected blood was centrifuged (10,000 g, 10 min, 4° C)
and plasma was removed and diluted 1:125 with 0.1 M Na3P04 buffer (pH 7.4). Plasma was
carefully checked to insure an absence of haemolysis. For AChE preparation, erythrocytes
were washed five times in isotonic saline, lysed in 9 volumes of 0.1 M Na3P04 buffer (pH 7.4)
containing 0.5% Triton-X (Sigma) and then were diluted with an additional 19 volumes of
buffer to a final dilution of 1:200.
Analysis of anticholinesterase activity was undertaken by utilizing a 25 µL sample of each
enzyme preparation, and was undertaken at their optimal working pH, 8.0, in 0.1 M Na3P04
buffer (0.75 mL total volume). Compounds were preincubated with enzymes (30 min, at room
temperature) and then were incubated with their respective substrates and with 5,5'-dithiobis-2-
nitrobenzoic acid (25 min, 37° C). The substrate/enzyme interaction was immediately halted
by the addition of excess enzyme inhibitor (physostigmine 1 × 10−5 M) and production of a
yellow thionitrobenzoate anion was then measured by spectrophotometer at 412 nm λ. To
correct for nonspecific substrate hydrolysis, aliquots were co-incubated under conditions of
absolute enzyme inhibition (by the addition of 1 ×10−5 M physostigmine (15a)), and the
associated alteration in absorbance was subtracted from that observed through the
concentration range of each test compound. Each agent was analyzed on four separate
occasions and assayed along-side physostigmine (15a), as a control and external standard
whose activity we have previously reported. 13–17, 19–21 The mean enzyme activity at each
concentration of test compound was then expressed as a percent of the activity in the absence
of compound. This was transformed into a logit format (where logit = ln(%activity/100 minus
%activity)) and then was plotted as a function of its log concentration. Inhibitory activity was
calculated as an IC50, defined as the concentration of compound (nM) required to inhibit 50%
of enzymatic activity, which was determined from a correlation between log concentration and
logit activity. Only results obtained from correlation coefficients of r2≥−0.98 were considered
acceptable. Studies that did not obtain this threshold were repeated.
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Computer Aided Molecular Modeling
Computer aided molecular modeling was undertaken using Sybyl version 7.0 (Tripos Inc., St.
Louis, MO). The numbering of the amino acid residues is based on that for TcAChE. Molecular
volume calculations were performed by using multiple volume comparison routine. The atomic
coordinates of the transition state of TcAChE were obtained from the protein data bank (PDB
entry: 1AMN)38, and were used for transition state studies. In undertaking this, i) molecules
of water were removed, ii) the small molecule, m- (N, N, N-trimethylammonio)-2,2,2-
trifluoroacetophenone (TMTFA), was extracted and, iii), the carbonyl carbon of TMTFA was
retained in the tetrahedral conformation. iv) The carbonyl carbon of the inhibitor, (−)-(3aS)-
N-2’-methylphenyl carbamoyl phenol of furobenzofuran (9a), was modified into the
tetrahedral conformation and then superimposed with that of TMTFA, keeping both phenyl
groups on the same side and, as much as possible, in a superimposed conformation. Thereafter,
compound 9a was merged into the active domain of TcAChE. The covalent bond between
carbonyl carbon of compound 9a and γ-O of Ser200 was created. To maintain the hydrogen
bonds associated with acylation, the distances between the NH of Gly118, Gly119, Ala201 and
oxygen of the ligand carbonyl, γ-O of Ser200 and a single H, the hydrogen and N of His440, the
NH of His440 and oxygen of Glu327 were constrained. All the residues outside a radius of 10
Å from the compound 9a were aggregated. The energy of the enzyme-inhibitor complex was
minimized with the conjugate gradient algorithm.
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X-ray crystallographic picture and corresponding chemical structure of 3
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Chiral HPLC analysisa of compounds 1, 4 and 5
a Instrument: HP1100; column: ChiraDex 5 µm; Flow-rate: 0.5 ml/min; Detection: UV 254
nm; Elutent: MeOH/H2O 45/55; Temperature: r.t. (Retention times, 1: 11.164 and 11.952 min;
4: 11.50 min; 5: 11.133 min).
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The union of molecular volume maps for the four active, S-configuration compounds 9a,
12a, 17a, 22a (green area) provide the enzyme-excluded volume. The molecular volume map
of compound 17b minus the enzyme-excluded volume is the estimate extra volume of 17b
(yellow meshed area)
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Close-up of compound 9a – TcAChE complex showing its covalent bonding with Ser200. The
yellow lines denote hydrogen bond to the residues in the oxyanion hole, i.e. Gly118, Gly119,
and Ala201, and in the catalytic triad, Ser200, His440, and Glu327.
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Chemical structures of clinically relevant cholinesterase inhibitors (Table 2)
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i) a, (−)-Menthy chloroformate, Et3N, benzen,N2, r.t., 1.5 hrs; b, recrystallized several times
in hexane, then in ethanol. ii) a, NaOH, MeOH, r.t., 1.5 hrs; b, r.t. 1N HCl
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i) a. LAH/Et2O, r.t., 1 hr; b. 1M HCl in Et2O, r.t., 0.5 hr. ii) Na, RNCO/Et2O, r.t., 0.5–1.0 hr.
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i) Na, RNCO/Et2O, r.t.
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Table 2
Comparison of the IC50 Values (± SEM) of Approved ChEIs of Clinical Interest Versus Freshly Prepared Human
Erythrocyte AChE and Plasma BChE (Figure 6)
IC 50 Value
* (nM)
Compound AChE BChE Selectivity
Tacrine 190 ± 40 47 ± 10 4-BChE
Donepezil 22 ± 8 4150 ± 1700 188-AChE
Rivastigmine 4150 ± 160 37 ± 5 122-BChE
Galanthamine 800 ± 60 7300 ± 830 9-AChE
(−)-Phenserine 22 ± 1.4 1560 ± 45 70-AChE
(−)-(3aS)-phenylcarbamate of physostigmine
Heptylstigmine 22 ± 2 5.0 ± 0.1 4-BChE
(−)-(3aS)-heptylcarbamate of physostigmine
Huperzine A 47 ± 22 >10,000 >212-AChE
BW284c51# 18 ± 8 48,000 2660-AChE
Iso-OMPA# 340,000 980 ± 550 35-BChE
*
IC50 values were determined in duplicate on a minimum of 4 different occasions from enzyme collected from the same individual as assays described
for Table 1.
#
BW284c51 (1,5-bis(4-allyldimethylammoniumphenyl)pentan-3-one dibromide) and Iso-OMPA (tetra(monoisopropyl)pyrophosphortetramide) are
classical selective inhibitors of AChE and BChE, respectively
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Table 3
Estimate Extra Volume* and the Ratio of Anticholinesterase Activity R/S




9b (+)-(3aR)-2’-methylphenylcarbamate 7.1 1.8
Dihydrobenzodioxepine series
12b (−)-(5R)-2’-methylphenylcarbamate 19.9 2.6
Physostigmine series
17b (+)-(3aR)-2’-methylphenylcarbamate 24.8 551
Physovenine series
22b (+)-(3aR)-2’-methylphenylcarbamate 19.4 11
*
Estimate Extra Volume = Volume of R-Configuration – Enzyme-Excluded Volume Map (Union of Volumes of Active S-Configuration Compounds:
9a, 12a, 17a and 22a).
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